Previous 10 | Next 10 |
The following slide deck was published by Exelixis, Inc. in conjunction with this Read more ...
Ahead of its JPM20 presentation, Exelixis (NASDAQ: EXEL ) announces preliminary 2019 results and its outlook for this year. More news on: Exelixis, Inc., Healthcare stocks news, Read more ...
– Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new potential IND candidates – – Presentation and webcast at 2020 J.P. Morgan Healthcare Conference on Tuesday, January ...
In 2016, Bank of America /Merrill Lynch released an intriguing report that examined the average long-term returns of growth stocks and value stocks between 1926 and 2016. What the report found was that, while both groups of stocks proved excellent over the long run, value stocks held the e...
— Presentation to be webcast on www.exelixis.com — Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 38 th Annual J.P. Morgan Healthcare C...
– Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients – – Initial data to be presented on February 13 at the 2020 American Society of Clinical Oncology’s Genitour...
Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...
New year, new decade, new chances to profit! While it's certain that the stock market can't continue to go up in a straight line, history also shows us that buying great stocks and holding them over the long run is a pretty surefire means to growing your wealth. What stocks should you buy to gr...
Eli Lilly (NYSE: LLY ) initiates a Phase 3 clinical trial, LIBRETTO-531 , evaluating selpercatinib (LOXO-292) in previously untreated patients with RET-mutation-positive medullary thyroid cancer, a Breakthrough Therapy indication. More news on: Eli Lilly and Company, Exelixis, Inc., San...
The markets have been performing very well in 2019 with the Dow Jones, the Nasdaq, and the S&P 500 all up more than 20% since the beginning of the year. That's great news for investors who are already holding stocks, but for those looking to get into the market for the first time, it means c...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...